A "meta-study" or "meta-analysis" analyzes multiple medical studies related to the same disease, treatment protocol, and outcome measurement to identify if there is an overall effect or not (e.g., treatment induces remission or causes adverse effects). It's advantage lies in the pooling and analysis of results across independent studies, which increases the population size, mitigates some experimental bias or inconsistent results from a single study, etc. Meta-studies are important for understanding the effectiveness (or not) of treatment, influencing clinical guidelines and for spurring new research directions. However, meta-studies are extremely time consuming to construct by hand and keep updated with the latest results. This limits both their breadth of coverage (since researchers will only invest the time for diseases they are interested in) and their practically. Yet, high-quality medical research is increasing at a staggering rate, and there is an opportunity to apply automation to this increasing body of knowledge, thereby expanding the benefits of meta-studies to (theoretically) all diseases and treatment, as they are published. That is, we envision, long term an automatic process for creating meta-studies across all diseases and treatments, and keeping those meta-studies up-to-date automatically. In this paper we demonstrate that there is potential to perform this task, point out future research directions to make this so, and, hopefully, spur significant interest in this compelling and important research direction at the intersection of medical research and machine learning.
The question is becoming more relevant today, with research trials ramping up to take advantage of big data, gene sequencing and precision medicine, experts say. For these trials to take place, researchers must recruit thousands of willing study participants. On June 2, patient engagement in medical research took center stage at a White House brainstorming session for physicians, tech gurus, Silicon Valley executives, research leaders, patient advocates and influential "e-patients." The session was titled: "Patients as partners in research."
The medicine of the future will incorporate elements from molecular biology and nanotechnology to develop point of care and home-based monitoring of health states. IBM Research partnered with the Icahn School of Medicine at Mount Sinai to develop exosome-based liquid biopsies using IBM's nanoDLD technology.
The clinical medicine award went to John B. Glen, who retired from the pharmaceutical firm AstraZeneca, for discovering and developing the world's most widely used drug for inducing anesthesia. Nicknamed "milk of amnesia" for its white, oily appearance, propofol quickly causes sedation and amnesia when injected through an IV. Besides operating rooms and emergency departments, it's used in outpatient clinics for procedures like colonoscopies.